Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Pulse rhythm01:30

Pulse rhythm

Pulse rhythm refers to the pattern of pulsations within specific intervals, offering valuable insights into the regularity or irregularity of the heart's beats as observed through the pattern of pulsation within specific intervals. A regular pulse exhibits a consistent heart rate with uniform waveforms and pulsation force, variations of which can be classified as normal, weak, or bounding.
Conversely, an irregular pulse pattern is termed dysrhythmia, stemming from disruptions in cardiac muscle...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The pathways for preferential conduction across the atrial walls.

Heart rhythm·2026
Same author

Real-time IVUS-guided retrieval of a coronary retained guidewire fragment: A case report.

Radiology case reports·2026
Same author

Atrial resynchronization: an overlooked concept in heart failure and conduction system pacing: review of selected literature with emphasis on atrial anatomy.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2026
Same author

Enhanced Detection of Atrial Fibrillation and Tachyarrhythmia Differentiation Using Atrial Electrograms in Single-chamber Implantable Cardioverter-defibrillators: A Retrospective Analysis.

The Journal of innovations in cardiac rhythm management·2026
Same author

Spontaneous Coronary Artery Dissection: Case Series and Review of Associated Cardiovascular Risks.

Cardiology in review·2025
Same author

Cardiogenic Shock in a Young South Asian Male With Cardiomyopathy due to a Pathogenic Variant of BAG3 Gene.

Case reports in medicine·2025

Related Experiment Video

Updated: May 25, 2026

Translational Rabbit Model of Chronic Cardiac Pacing
06:14

Translational Rabbit Model of Chronic Cardiac Pacing

Published on: January 6, 2023

Optimizing pacemaker longevity with pacing mode and settings programming: results from a pacemaker multicenter

Henri Benkemoun1, Jean Sacrez, Philippe Lagrange

  • 1Clinique St Pierre, Perpignan, France. henri.benkemoun@wanadoo.fr

Pacing and Clinical Electrophysiology : PACE
|February 8, 2012
PubMed
Summary

Reprogramming dual-chamber pacemakers, especially using SafeR mode and optimizing amplitudes, significantly extends device longevity. Adjusting settings can add over two years to pacemaker life, improving patient care.

More Related Videos

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation
08:56

Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation

Published on: September 24, 2021

Related Experiment Videos

Last Updated: May 25, 2026

Translational Rabbit Model of Chronic Cardiac Pacing
06:14

Translational Rabbit Model of Chronic Cardiac Pacing

Published on: January 6, 2023

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation
08:56

Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation

Published on: September 24, 2021

Area of Science:

  • Cardiology
  • Biomedical Engineering
  • Medical Device Technology

Background:

  • Dual-chamber pacemakers are crucial for managing cardiac rhythm disorders.
  • Understanding factors influencing pacemaker longevity is essential for optimizing patient management and device selection.

Purpose of the Study:

  • To investigate the impact of device settings on the projected longevity of dual-chamber pacemakers.
  • To identify specific programming parameters that correlate with extended device lifespan.

Main Methods:

  • Analysis of data from patients implanted with dual-chamber devices (Symphony™) between 2003 and 2006.
  • Retrieved programmer files to assess device-estimated longevity based on algorithm prediction and device settings.

Main Results:

  • A significant increase in longevity was observed in devices that underwent reprogramming (134.4 months) compared to those that did not (103.4 months).
  • Programming in SafeR mode (minimized ventricular pacing) and reducing atrial/ventricular amplitudes were associated with substantial increases in mean longevity (+23.9 months and +26.9/+29.6 months, respectively).

Conclusions:

  • Device reprogramming significantly impacts the expected longevity of dual-chamber pacemakers.
  • Optimizing pacing modes and output amplitudes are key strategies for maximizing pacemaker battery life.